- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | 137 | PR Newswire | TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA... ► Artikel lesen | |
| 01.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer | 741 | PR Newswire | BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment... ► Artikel lesen | |
| 22.05. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 07.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | 519 | PR Newswire | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| 06.01. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 321 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen | |
| 14.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | 353 | PR Newswire | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| 08.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology ... | 337 | PR Newswire | TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences
Concurrent equity investment of $25 Million from CK Life Sciences... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,45 | +3,13 % | Alarm bei BMW! Ausverkauf bei BioNTech! Unterbewertung bei Desert Gold Aktie! | Alarm bei BMW. Erst hat man Aktionäre mit einer Gewinnwarnung schockiert. Das Geschäft in China ist eingebrochen. Jetzt ziehen Analysten ihre Konsequenzen. Die Schätzungen und Kursziele werden reduziert.... ► Artikel lesen | |
| QIAGEN | 34,570 | +0,14 % | Qiagen und das KI-Thema | Die Analysten der DZ Bank sehen bei Qiagen viele aussichtsreiche Wachstumstreiber. Mittelfristig zeigen sich dadurch gute Perspektiven. Beim Thema KI profitiert Qiagen auf mehreren Ebenen, sei es bei... ► Artikel lesen | |
| VALNEVA | 2,271 | +0,22 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| NOVAVAX | 8,160 | +4,48 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| PALATIN TECHNOLOGIES | 10,100 | -11,71 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| BRAIN BIOTECH | 2,730 | -1,44 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech veröffentlicht Halbjahreszahlen für das Geschäftsjahr 2025/26 und bestätigt Gesamtjahresprognose | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Halbjahresergebnis/Halbjahresbericht
BRAIN Biotech veröffentlicht Halbjahreszahlen für das Geschäftsjahr 2025/26 und bestätigt Gesamtjahresprognose... ► Artikel lesen | |
| VIVOSIM LABS | 1,050 | 0,00 % | VivoSim Labs, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,780 | +1,71 % | COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment | TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") announced the next steps in connection with changes to the Company's... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,075 | +4,37 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,940 | +0,81 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| XOMA ROYALTY | 37,400 | +0,54 % | XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date | EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 0,993 | +2,32 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen |
Das Unternehmen TRANSCODE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,33 % bei einem Aktienkurs von 5,185 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.